Latest Content

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers.

The FDA granted sibeprenlimab accelerated approval for nephropathy after data showed it cut IgA nephropathy proteinuria by about 50% via APRIL inhibition.

These new data show that 64.8% of US adults take at least 1 prescription medication each year.

Providing monthly produce prescriptions to patients with diabetes at risk for food insecurity did not significantly improve cardiometabolic parameters.

NHANES data reveal a US sleep crisis: Chronic sleep deprivation gaps tied to education, BMI, and food security, via Blinder-Oaxaca decomposition.

The serial monitoring of muscle-specific kinase (MuSK) antibodies could help in assessing the severity of the disease.

New IQ data show those with idiopathic hypersomnia and narcolepsy retain normal cognitive ability; fatigue, not sleepiness, hits working memory.

An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing.

An analysis shows that oral semaglutide significantly lowers the risk of heart failure (HF) outcomes in patients with type 2 diabetes and a history of HF.